Welcome to our dedicated page for Aurora Spine news (Ticker: ASAPF), a resource for investors and traders seeking the latest updates and insights on Aurora Spine stock.
Aurora Spine Corporation develops and manufactures minimally invasive spinal implants and interventional pain management technologies for spinal surgery. News about ASAPF commonly covers product launches, patent issuances and commercialization updates across the company's spine portfolio, including DEXA Technology bone density-matched implants, ZIP implants, SiLO systems, Hydra A.E.R.O. facet fusion products and Aurora Biologics.
Recurring updates also include financial results, sales-force and product-adoption commentary, medical meeting participation and intellectual-property expansion through U.S. patents. Company releases emphasize implant designs that match patient bone density, fusion and motion-preservation applications, and integrated biologic support for spinal fusion procedures.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) will participate in the Lytham Partners Winter 2021 Investor Conference from December 13-16, 2021. The company will host a webcasted Fireside Chat on December 13 at 11:00 am ET, discussing its vision for 2022, and will conduct one-on-one virtual investor meetings. Interested parties can watch the webcast on Aurora Spine's website or via a provided link. The company specializes in innovative spinal surgery devices aimed at improving surgical outcomes.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) has partnered with PRIA Healthcare to improve patient access to its innovative spinal devices, including ZIP® and SiLO™. PRIA brings 10 years of medtech experience, assisting companies in navigating insurance systems to facilitate patient access to emerging medical technologies. Aurora's leadership expresses confidence in PRIA's capabilities, emphasizing a shared commitment to enhancing patient outcomes through advanced medical solutions.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) will participate in the Lytham Partners Fall 2021 Investor Conference from October 5-7, 2021. The President and CEO, Trent Northcutt, is set to present on October 5 at 2:45 PM ET. A webcast of the presentation will be accessible on the company’s website, and it will be archived for later viewing. Northcutt, along with CFO Chad Clouse, will also hold one-on-one meetings during the event. The company focuses on innovative spinal implant technologies and is anticipating commercialization of new products in the upcoming quarters.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) announced its participation at the 2021 North American Spine Society Annual Meeting from September 29 to October 2, 2021, in Boston, Massachusetts. The company will showcase its FDA-cleared DEXA-C anterior fusion cages and SiLO™ SI Fusion System, designed for spinal surgery. Aurora's CEO emphasized growing adoption of their products post-COVID, particularly the innovative DEXA technology aimed at improving patient outcomes.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) has successfully closed its private placement, raising C$6,508,139.40 by issuing 11,220,930 common shares and warrants. Each warrant allows the purchase of a common share at C$0.75, maturing three years from the closing date. The funds will be allocated for sales, marketing, R&D, and working capital. A.G.P./Alliance Global Partners acted as the exclusive placement agent, receiving a 7% cash commission and broker warrants.
Aurora Spine Corporation (TSXV: ASG; OTCQB: ASAPF) announced a private placement to raise approximately C$6.5 million through the issuance of up to 11,220,930 common shares and warrants. The shares and warrants will be sold at C$0.58 each, with warrants allowing the purchase of additional shares at C$0.75 before three years. The private placement, expected to close around September 17, 2021, is subject to regulatory approvals. A.G.P./Alliance Global Partners is the exclusive placement agent in the U.S., and a 7% cash commission will be paid to them.
Aurora Spine Corporation (ASAPF) announced the enrollment of initial patients in a pivotal multi-center study for its ZIP® Interspinous Fixation device, targeting back pain due to degenerative disc disease. The REFINE Screwless™ ZIP Study aims to evaluate the device across 10 surgical sites in the US with an expected enrollment of approximately 100 patients. This minimally invasive alternative to traditional spinal surgery promises reduced recovery time and increased patient mobility. The ZIP System, cleared by the FDA in 2013, has been used in over 5,000 procedures globally, demonstrating its safety and effectiveness.
Aurora Spine Corporation has received FDA 510(k) Clearance for its DEXA-C, the first cervical cage utilizing patented DEXA Technology™ designed to match patient bone density. This innovation aims to enhance spinal surgery outcomes by promoting faster bone growth and providing superior fixation. The DEXA-C line represents a significant advancement in personalized implants, moving away from traditional one-size-fits-all solutions. Experts, including Dr. Sebastian Koga, praise its potential to revolutionize interbody fusion and replace existing materials.
Aurora Spine Corporation (OTCQB: ASAPF) has announced its participation in the Alliance Global Partners’ Virtual MedTech Summer Conference on July 29, 2021. President and CEO Trent Northcutt expressed gratitude for the opportunity to present the company’s innovative, minimally invasive spinal implant technologies aimed at enhancing surgical outcomes. This event will feature one-on-one investor meetings, and interested investors can arrange meetings through Alliance Global Partners. Aurora Spine aims to expand its market presence by introducing new products targeting pain management.
Aurora Spine Corporation (OTCQB: ASAPF) will participate in the Third Annual ASPN Conference from July 22-25, 2021, at the Loews Miami Beach Hotel. The company will sponsor a breakfast symposium and a hands-on training lab featuring 19 lab stations for pain procedures and minimally invasive spinal surgery. Course directors include renowned surgeons, enhancing education on Aurora's products. Additionally, on July 23, Aurora will showcase its pain products in a joint breakfast and product theater.
CEO Trent Northcutt emphasizes the importance of in-person events for engaging with healthcare professionals post-pandemic.